SCHEMBL4768519

SCHEMBL4768519

COC(=O)C(C)(C)Cc1ccc(Br)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.45
LMNA P02545 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.44
KDM4E B2RXH2 1/20 0.44
GLA P06280 1/20 0.44
PTPRB P23467 2/20 0.42
HPGD P15428 2/20 0.41
MEN1 O00255 2/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
ALDH1A1 P00352 4/20 0.40
PTPN1 P18031 2/20 0.39
PTPN2 P17706 1/20 0.39
PTPRA P18433 1/20 0.39
POLB P06746 1/20 0.39
CTDSP1 Q9GZU7 1/20 0.39
MMP1 P03956 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11509018 0.91 PTPRB (0.47) PTPRBPTPN1PTPN2PTPRAMMP8
SCHEMBL5567033 0.86 PTPRB (0.42) KMT2APTPRBMEN1PTPN1PTPN2
SCHEMBL11646444 0.85 PTPRB (0.44) PTPRBPTPN1PTPN2PTPRAMMP1
SCHEMBL5256182 0.84 CTSS (0.41) KMT2ALMNASMN1; SMN2L3MBTL1KDM4E
SCHEMBL14290217 0.84 ALDH1A1 (0.45) LMNASMN1; SMN2PTPRBHPGDNPC1
SCHEMBL11530777 0.84 HPGD (0.45) SMN1; SMN2PTPRBHPGDNPC1RAB9A
SCHEMBL3665931 0.84 ESR1 (0.53) KMT2AKDM4EPTPRBMEN1PTPN1
SCHEMBL15059305 0.84 EPHX2 (0.44) LMNAKDM4EPTPRBHPGDGAA
SCHEMBL8879088 0.83 MEN1 (0.44) KMT2ASMN1; SMN2PTPRBMEN1PTPN1
SCHEMBL7699138 0.83 BLM (0.47) KMT2ALMNASMN1; SMN2L3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11261190-B2 Dihydropyrimidine compounds and uses thereof in medicine SUNSHINE LAKE PHARMA CO., LTD. (CN) 2022-03-01 US disclosed
US-11142527-B2 Dihydropyrimidine compounds and uses thereof in medicine SUNSHINE LAKE PHARMA CO., LTD. (CN) 2021-10-12 US disclosed
CN-109678859-B Dihydropyrimidine compound and application thereof in medicine 广东东阳光药业有限公司 2020-12-29 CN disclosed
US-20200283445-A1 DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2020-09-10 US disclosed
US-20200283445-A1 DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2020-09-10 US disclosed
CN-109111451-B Dihydropyrimidine compound and application thereof in medicine 广东东阳光药业有限公司 2020-08-11 CN disclosed
US-20200115381-A1 DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED (CN) 2020-04-16 US disclosed
WO-2019076310-A1 DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2019-04-25 WO disclosed
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 EP disclosed
US-6875761-B2 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. (JP) 2005-04-05 US disclosed
EP-0749964-B1 N-Heterocyclyl biphenyl sulfonamides ASTRAZENECA AB (SE) 2001-10-04 EP disclosed
US-6258817-B1 PRODRUGS, HYPOTENSIVE AGENTS AND CARDIOVASCULAR DISORDERS ZENECA LTD. (GB) 2001-07-10 US disclosed
EP-1020445-A1 FUSED PYRIDINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-07-19 EP disclosed
US-6060475-A Substituted pyrazin-2-yl-sulphonamide-(3-pyridyl) compounds and uses thereof ZENECA LIMITED (GB) 2000-05-09 US disclosed
US-5866568-A ENDOTHELIN RECEPTOR ANTAGONIST ACTIVITY ZENECA LIMITED (GB) 1999-02-02 US disclosed
CN-1192739-A N-heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists ZENECA LTD (GB) 1998-09-09 CN disclosed
EP-0832082-A1 N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS ZENECA LIMITED (GB) 1998-04-01 EP disclosed
US-5668137-A N-heterocyclic sulfonamides having endothelin receptor activity ZENECA LTD. (GB) 1997-09-16 US disclosed
EP-0749964-A1 N-Heterocyclyl biphenyl sulfonamides ZENECA LIMITED (GB) 1996-12-27 EP disclosed
WO-1996040681-A1 N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS ZENECA LIMITED (GB) 1996-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200115381-A1 DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE DPYD, SLC10A1, DHODH KMT2A 2794/4885LMNA 2235/4885SMN1; SMN2 1893/4885
US-20200283445-A1 DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE TPMT, DPYD, SLC10A1 KMT2A 3338/4885LMNA 3744/4885SMN1; SMN2 1216/4885
US-11142527-B2 Dihydropyrimidine compounds and uses thereof in medicine DPYD, SLC10A1, DHODH KMT2A 2794/4885LMNA 2235/4885SMN1; SMN2 1893/4885
US-11261190-B2 Dihydropyrimidine compounds and uses thereof in medicine DPYD, TPMT, SLC10A1 KMT2A 3391/4885LMNA 3134/4885SMN1; SMN2 1307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.